Skip to main content
SpringerLink
Log in

Therapeutic efficacy of two different cytostatic-linked phosphonates in combination with razoxane in the transplantable osteosarcoma of the rat

  • Published:
Clinical & Experimental Metastasis Aims and scope Submit manuscript

Abstract

Two new compounds, 4-[4-[bis-(2-chloroethyl)-amino-]phenyl]-1-hydroxybutane-1,1-bisphosphonic acid (BAD) and aminotris-(methylenephosphonato)diamminoplatinum(ii) (ADP) that both have cytostatic and osteotropic properties, have shown good therapeutic efficacy against an osteosarcoma which metastasizes and kills by lung metastases. We therefore combined each of these drugs with the antimetastatic agent razoxane. Razoxane (20 mg/kg i.p., 5 days/week for 6 weeks) was administered in combination with either BAD (30 mg/kg i.p.) or ADP (37·5 mg/kg i.v.) twice weekly for 3 weeks. Tumour volumes, body weight, survival time and occurrence of metastases were recorded, in addition to the measurement of the metastasis area compared to the total lung area in serial histological lung samples. In both experiments, razoxane effected a significant increase in life span while being ineffective in tumour inhibition. Razoxane in combination with BAD displayed an enhanced anticancer activity which was not significant. ADP had a good antineoplastic activity and a large increase in survival time (144 per cent I LS). Razoxane used in combination with ADP did not influence antitumour efficacy. Median survivals of both ADP-treated groups were significantly longer than the razoxane-treated group. Analysis of the lung metastasis area showed a maximum of 57 per cent for the controls while all treated groups occupied a lesser area. The lowest metastases area was found with the combination treatment BAD + RAZ (18 per cent). This was considered an antimetastatic effect, while ADP treatment effected a time delay only. No change in metastatic pattern was observed in any of the treatment groups. Histological examination showed no effect on the capillaries in the proliferating region of the tumours that could account for the lower occurrence of metastases.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Adami, S.,Salvagno, G.,Guarrera, G.,Montesanti, F.,Garavelli, S.,Rosini, S., andLocascio, V., 1986, Treatment of Paget's disease of bone with intravenous 4-amino-1-hydroxybutylidene-1,1-bisphosphonate.Calcified Tissue International, 39, 226–229.

    PubMed  Google Scholar 

  2. Albanese, R., andWatkins, P. A., 1985, The mutagenic activity of razoxane (ICRF 159): an anticancer agent.British Journal of Cancer,52 (5), 725–731.

    PubMed  Google Scholar 

  3. Attardo-Parrinello, G.,Merlini, G.,Pavesi, F.,Crema, F.,Fiorentini, M. L., andAscari, E., 1987, Effects of a new aminodiphosphonate (aminohydroxybutylidene diphosphonate) in patients with osteolytic lesions from metastases and myelomatosis.Archives of International Medicine,147, 1629–1633.

    Google Scholar 

  4. Boonekamp, P.,Van Der Wee-Pals, L. J. A.,Van Wijk-Van Lennep, M. M. L.,Wil Thesing, C., andBijvoet, O. L. M., 1986, Two modes of action of bisphophosphonates on osteoclastic resorption of mineralized matrix.Bone and Mineral,1, 27–39.

    PubMed  Google Scholar 

  5. Canfield, R. E., 1987, Rationale for disphosphonate therapy in hypercalcemia of malignancy.American Journal of Medicine,82 (2A), 1–5.

    Google Scholar 

  6. Coleman, R. E., andRubens, R. D., 1987, 3(Amino-1,1-hydroxypropylidene) bisphosphonate (APD) for hypercalcemia of breast cancer.British Journal of Cancer,56, 465–469.

    PubMed  Google Scholar 

  7. Fischer, V. W.,Wang, G. M., andHobart. N. H., 1986, Mitigation of an anthracycline-induced cardiomyopathy by pretreatment with razoxane: a quantitative morphological assessment.Virchows Archiv,51 (4), 353–361.

    PubMed  Google Scholar 

  8. Gilbert, J. M., 1986, Trials of adjuvant chemotherapy in colorectal cancer.Drugs Experimental Clinical Research,12 (1-3), 201–210.

    Google Scholar 

  9. Gilbert, J. M.,Hellmann, K.,Evans, M.,Cassell, P. G.,Taylor, R. H.,Stoodley, B.,Ellis, H., andWastell, C., 1986, Randomized trial of oral adjuvant razoxane (ICRF 159) in resectable colorectal cancer: five year follow up.British Journal of Surgery,73 (6), 446–450.

    PubMed  Google Scholar 

  10. Harinck, H. I. J.,Papapoulos, S. E.,Blanksma, H. J.,Moolenaar, A. J.,Vermeij, P., andBijvoet, O. L. M., 1987, Paget's disease of bone: early and late reponses to three different modes of treatment with aminohydroxypropylidene bisphosphonate (APD). British Medical Journal, 295, 1301–1305.

    PubMed  Google Scholar 

  11. Hellmann, K., 1984, Razoxane. Clinical Chemotherapy, vol. III: Antineoplastic Chemotherapy, edited by H. P. Kuemmerle (New York: Thième Stratton), pp. 275–282.

  12. Herman, E.,Witiak, D.,Hellmann, K., andWaravdekar, V., 1982, Biological properties of ICRF-159 and related bis(dioxopiperazine) compounds.Advances in Pharmacology and Chemotherapy,19, 294–298.

    Google Scholar 

  13. Kalbfleisch, J. D., andPrentice, R. E., 1980, The Statistical Analysis of Failure Time Data. (New York: Wiley).

    Google Scholar 

  14. Klenner, T.,Münch, H.,Schmähl, D., andKeppler, B., 1988, Efficacy of new cisplatin-linked bisphosphonates in transplantable rat osteosarcoma.Journal of Cancer Research and Clinical Oncology, 114, S162.

    Google Scholar 

  15. Klenner, T.,Blum, H.,Krempien, B., andSchmähl, D., 1988, Protective effect of 3-disodium-hydroxy-propylidene-1,1-bisphosphonate derivatives in prophylactic treatment of osteolytic bone-lesions induced by Walker carcinosarcoma 256 B in the rat.European Society on Medical Oncology, Abstracts of the 13th Congress,C70, 278(P).

  16. Koziol, A. J., andDonna, A. M., 1981, A distribution-free test for tumour growth curve analysis with application to an animal tumour immunotherapy experiment.Biometrics,37, 383–390.

    PubMed  Google Scholar 

  17. Krempien, B.,Wingen, F.,Eichmann, T.,Müller, M., andSchmähl, D., 1988, Protective effects of a prophylactic treatment with the bisphosphonate 3-amino-lhydroxypropane-1,1-bisphosphonic acid on the development of tumor osteopathies in the rat: experimental studies with the Walker carcinosarcoma 256.Oncology,45, 41–46.

    PubMed  Google Scholar 

  18. Löwik, C. W. G. M.,Van Der Pluijm, G., andBijvoet, O. L. M., 1987, Migration and phenotypic transformation of osteoclast-precursors into mature osteoclasts: the effect of dimethyl-APD (Me2APD).Calcified Tissue International,41 (Suppl. 2), 49.

    Google Scholar 

  19. Marie, P. J.,Hott, M., andGarba, M., 1985, Inhibition by aminohydroxypropylidene bisphosphonate (AHPrBP) of 1,25(OH)2 vitamin D3-induced stimulated bone turnover in the mouse.Calcified Tissue International,37, 268–275.

    PubMed  Google Scholar 

  20. Metzger, U. F.,Ghosh, B. C., andKisner, D. L., 1985, Adjuvant treatment of colorectal cancer current status and concepts.Cancer Chemotherapy and Pharmacology,14(1), 1–8.

    PubMed  Google Scholar 

  21. Meunier, P. J.,Chapuy, M.,Delmas, P.,Charhon, S.,Edouard, C., andArlot, M., 1987, Intravenous disodium etidronate therapy in Paget's disease of bone and hypercalcemia of malignancy.American Journal of Medicine, 82 (2A), 71–78.

    PubMed  Google Scholar 

  22. Merriman, R. L.,Tanzer, L. R.,Shakelford, K. A.,Bemis, K. G.,Campbell, J. B., andMatsumoto, K., 1988, Inhibition of spontaneous metastasis of Lewis lung carcinoma with a variety of antithrombotic agents does not increase survival.Clinical and Experimental Metastasis,6, (Suppl. 1), p. 98.

    Google Scholar 

  23. Papaloulos, S. E.,Aleman, B. M. P.,Hoekman, K.,Löwik, C. W. G. M., andBijvoet, O. L. M., 1987,In vitro assessment of the potency of bisphosphonates can be predictably confirmed in a patient-observer independent clinical model.Calcified Tissue International,41 (Suppl. 2), p. 60.

    Google Scholar 

  24. Reitsma, H. P.,Bijvoet, O. L. M.,Potokar, M.,Van Der Wee-Pals, L. J. A., andVan Wijk-Van Lennep, M. M. L., 1983, Apposition and resorption of bone during oral treatment with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD).Calcified Tissue International,35, 357–361.

    PubMed  Google Scholar 

  25. Sava, G.,Giraldi, T.,Perissin, L.,Zorzet, S., andDecorti, G., 1987, Effects of antimetastatic, antiinvasive and cytotoxic agents on the growth and spread of transplantable leukemias in mice.Clinical and Experimental Metastasis,5 (1), 27–34.

    PubMed  Google Scholar 

  26. Schenk, R.,Eggli, P.,Fleisch, H., andRosini, S., 1986, Quantitative morphometric evaluation of the inhibitory activity of new aminobisphosphonates on bone resorption in the rat.Calcified Tissue International,38, 342–349.

    PubMed  Google Scholar 

  27. Scheulen, M. E., 1985, Kardiotoxische Nebenwirkungen von Zytostatika. Die Anthrazylin-Kardiotoxizität.Münchner Medizinische Wochenschrift,127 (37),862–8666.

    Google Scholar 

  28. Scher, H. I., andYagoda, A., 1987, Bone metastasis: Pathogenesis, treatment, and rationale for use of resorption inhibitors.American Journal of Medicine,82 (2A), 6–28.

    PubMed  Google Scholar 

  29. Shinoda, H.,Adamek, G.,Felix, R.,Fleisch, H.,Schenk, R., andHagan, P., 1983, Structure-Activity Relationships of various Bisphosphonates.Calcified Tissue International,35, 87–99.

    PubMed  Google Scholar 

  30. Van Holten-Verzantvoort, A. T.,Bijvoet, O. L. M.,Hermans, J.,Harinck, H. I. J.,Elte, J. W. F.,Beex, L. V. A. M.,Cleton, F. J.,Kroon, H. M.,Vermey, P.,Neijt, J. P., andBiljham, G., 1987, Reduced morbidity from skeletal metastases in breast cancer patients during long-term bisphosphonate (APD) treatment.Lancet,10, 983–985.

    Google Scholar 

  31. Wingen, F.,Schmahl, D.,Berger, M. R., andSpring, H., 1984, Intraosseously transplantable osteosarcoma with regularly disseminating pulmonary metastases in rats.Cancer Letters,23, 201–211.

    PubMed  Google Scholar 

  32. Wingen, F.,Eichmann, T.,Manegold, C., andKrempien, B., 1986, Effects of new bisphosphonic acids on tumor-induced bone destruction in the rat.Journal of Cancer Research and Clinical Oncology,111 (1), 35–46.

    PubMed  Google Scholar 

  33. Wingen, F.,Sterz, H.,Blum, H.,Möller, H.,Pittermann, W.,Pool, B. L.,Sinn, H. J.Spring, H., andSchmähl, D., 1986, Synthesis, antitumor activity, distribution and toxicity of 4-[4-bis(2-chloroethyl)amino)phenyl]-1-hydroxybutane-1,1-bisphosphonate (BAD), a new lost derivative with increased accumulation in rat osteosarcoma.Journal of Cancer Research and Clinical Oncology,111, 209–219.

    PubMed  Google Scholar 

  34. Wingen, F., andSchmähl, D., 1987, Pharmakokinetiks of the osteotropic diphosphonate 3-amino-1-hydroxypropane-1,1-diphosphonic acid in mammals.Drug Research,37 (II), 1037–1042.

    PubMed  Google Scholar 

  35. Wingen, F.,Spring, H.,Schm-hl, D., 1987, Antimetastatic effects of razoxane in a rat osteosarcoma model.Clinical and Experimental Metastasis,5, 9–16.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute of Toxicology and Chemotherapy, German Cancer Research Center, Im Neuenheimer Feld 280, Heidelberg, F.R.G.

    T. Klenner, F. Wingen, P. Valenzuela-Paz & D. Schmähl

  2. Institute of Inorganic Chemistry, University of Heidelberg, Im Neuenheimer Feld 270, Heidelberg, F.R.G.

    B. Keppler

  3. Institute of Experimental Pathology, German Cancer Research Center, Im Neuenheimer Feld 280, 6900, Heidelberg, F.R.G.

    F. Amelung

Authors
  1. T. Klenner
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. F. Wingen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. B. Keppler
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. P. Valenzuela-Paz
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. F. Amelung
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. D. Schmähl
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Klenner, T., Wingen, F., Keppler, B. et al. Therapeutic efficacy of two different cytostatic-linked phosphonates in combination with razoxane in the transplantable osteosarcoma of the rat. Clin Exp Metast 8, 345–359 (1990). https://doi.org/10.1007/BF01810680

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01810680

Keywords

Search

Navigation